<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T05:24:30Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7566958" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7566958</identifier>
        <datestamp>2020-10-16</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">8704895</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">5536</journal-id>
              <journal-id journal-id-type="nlm-ta">Leukemia</journal-id>
              <journal-id journal-id-type="iso-abbrev">Leukemia</journal-id>
              <journal-title-group>
                <journal-title>Leukemia</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0887-6924</issn>
              <issn pub-type="epub">1476-5551</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7566958</article-id>
              <article-id pub-id-type="pmcid">PMC7566958</article-id>
              <article-id pub-id-type="pmc-uid">7566958</article-id>
              <article-id pub-id-type="pmid">28819281</article-id>
              <article-id pub-id-type="pmid">28819281</article-id>
              <article-id pub-id-type="doi">10.1038/leu.2017.264</article-id>
              <article-id pub-id-type="manuscript">nihpa890534</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Mechanisms of Resistance to the BCR-ABL1 Allosteric Inhibitor Asciminib</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Qiang</surname>
                    <given-names>Wang</given-names>
                  </name>
                  <xref ref-type="aff" rid="A1">1</xref>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref rid="FN1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Antelope</surname>
                    <given-names>Orlando</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref rid="FN1" ref-type="author-notes">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zabriskie</surname>
                    <given-names>Matthew S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pomicter</surname>
                    <given-names>Anthony D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vellore</surname>
                    <given-names>Nadeem A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Szankasi</surname>
                    <given-names>Philippe</given-names>
                  </name>
                  <xref ref-type="aff" rid="A3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rea</surname>
                    <given-names>Delphine</given-names>
                  </name>
                  <xref ref-type="aff" rid="A4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cayuela</surname>
                    <given-names>Jean Michel</given-names>
                  </name>
                  <xref ref-type="aff" rid="A5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kelley</surname>
                    <given-names>Todd W.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A3">3</xref>
                  <xref ref-type="aff" rid="A6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Deininger</surname>
                    <given-names>Michael W.</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>O’Hare</surname>
                    <given-names>Thomas</given-names>
                  </name>
                  <xref ref-type="aff" rid="A2">2</xref>
                  <xref ref-type="aff" rid="A7">7</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>1</label>Department of Hematology, Nanfang Hospital, Southern Medical University, GuangZhou, China</aff>
              <aff id="A2"><label>2</label>Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA</aff>
              <aff id="A3"><label>3</label>ARUP Laboratories, Salt Lake City, UT, USA</aff>
              <aff id="A4"><label>4</label>Service d’Hématologie Adulte and INSERM UMR1160, Hospital Saint-Louis, 75010 Paris, France</aff>
              <aff id="A5"><label>5</label>Laboratory of Hematology, University Hospital Saint-Louis and EA3518, University Paris Diderot, Paris</aff>
              <aff id="A6"><label>6</label>Department of Pathology, University of Utah, Salt Lake City, UT, USA</aff>
              <aff id="A7"><label>7</label>Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA</aff>
              <author-notes>
                <fn fn-type="equal" id="FN1">
                  <label>*</label>
                  <p id="P1">equal contributions</p>
                </fn>
                <corresp id="CR1">
                  <email>Thomas.OHare@hci.utah.edu</email>
                </corresp>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>4</day>
                <month>10</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>18</day>
                <month>8</month>
                <year>2017</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>12</month>
                <year>2017</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>16</day>
                <month>10</month>
                <year>2020</year>
              </pub-date>
              <volume>31</volume>
              <issue>12</issue>
              <fpage>2844</fpage>
              <lpage>2847</lpage>
              <!--elocation-id from pubmed: 10.1038/leu.2017.264-->
              <permissions>
                <license>
                  <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<uri xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
                </license>
              </permissions>
            </article-meta>
          </front>
          <body>
            <p id="P2">The development of asciminib (ABL001)<sup><xref rid="R1" ref-type="bibr">1</xref></sup>, a low nanomolar allosteric BCR-ABL1 tyrosine kinase inhibitor (TKI), is the culmination of programs in academic and pharmaceutical industry laboratories spanning more than a decade. Currently in clinical trials for relapsed/refractory Philadelphia chromosome-positive (Ph+) leukemia patients (<ext-link ext-link-type="uri" xlink:href="http://Clinicaltrials.gov">ClinicalTrials.gov</ext-link>: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02081378">NCT02081378</ext-link>), asciminib represents a major advance from the structurally related, micromolar-potency tool compounds GNF-2 and GNF-5<sup><xref rid="R2" ref-type="bibr">2</xref>–<xref rid="R4" ref-type="bibr">4</xref></sup>. We investigated mechanisms of asciminib resistance and identified two major categories: (1) upregulation of the ABCG2 efflux pump, resulting in undetectable intracellular asciminib levels, and (2) emergence of <italic>BCR-ABL1</italic> mutations at the myristoyl-binding site and at a distant residue.</p>
            <p id="P3">We generated five asciminib-resistant, BCR-ABL1-positive cell lines by adapting to increasing concentrations of asciminib : K562<sup>asciminib-R</sup>, LAMA84<sup>asciminib-R</sup>, KYO1<sup>asciminib-R</sup>, Ba/F3 BCR-ABL1<sup>asciminib-R</sup> and KCL-22<sup>asciminib-R</sup> cells (<xref rid="SD5" ref-type="supplementary-material">Supplemental Methods</xref>). In K562<sup>asciminib-R</sup> cells, methanethiosulfonate (MTS)-based cell proliferation assays demonstrated a ~60-fold increase in asciminib IC<sub>50</sub> compared to parental K562 cells, despite remaining sensitive to the ATP-site TKIs imatinib, nilotinib, dasatinib and ponatinib (<xref rid="F1" ref-type="fig">Figure 1a</xref>; <xref rid="SD6" ref-type="supplementary-material">Table S1</xref>). Immunoblot analysis revealed similar results, showing marked restoration of BCR-ABL1 tyrosine kinase activity and downstream STAT5 tyrosine phosphorylation in the presence of asciminib but not ponatinib (<xref rid="SD8" ref-type="supplementary-material">Figure S1a</xref>). However, Next-Generation Sequencing (NGS) and Sanger sequencing of the <italic>BCR-ABL1</italic> kinase domain identified no mutations (<xref rid="SD7" ref-type="supplementary-material">Table S2</xref>)<sup><xref rid="R5" ref-type="bibr">5</xref></sup>. To check for the possibility of reduced intracellular drug concentrations, asciminib levels were measured following treatment using a customized liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) method<sup><xref rid="R6" ref-type="bibr">6</xref></sup>. Asciminib was undetectable in K562<sup>asciminib-R</sup> cells but present at substantial levels in parental K562 cells (<xref rid="SD8" ref-type="supplementary-material">Figure S1b</xref>), with an inhibitor-based screen for potential involvement of efflux pumps (<xref rid="SD8" ref-type="supplementary-material">Figure S1c</xref>) and analysis by qPCR and immunoblot (<xref rid="F1" ref-type="fig">Figure 1b</xref>) all implicating ABCG2. Cell proliferation experiments revealed that the ABCG2 inhibitor Ko143 restored asciminib effectiveness against K562<sup>asciminib-R</sup> cells but had no effect on the asciminib IC<sub>50</sub> for K562 cells (<xref rid="F1" ref-type="fig">Figure 1c</xref>). Similar results were obtained for LAMA84<sup>asciminib-R</sup> (<xref rid="SD9" ref-type="supplementary-material">Figure S2</xref>; <xref rid="SD6" ref-type="supplementary-material">Table S1</xref>, <xref rid="SD7" ref-type="supplementary-material">S2</xref>) and KYO1<sup>asciminib-R</sup> cells (<xref rid="SD10" ref-type="supplementary-material">Figure S3</xref>; <xref rid="SD6" ref-type="supplementary-material">Table S1</xref>, <xref rid="SD7" ref-type="supplementary-material">S2</xref>). Our findings support ABCG2-mediated efflux of asciminib as the major mechanism of resistance in these cell lines, warrant its profiling among patients with asciminib resistance in the clinic, and suggest that combining asciminib with an ABCG2 inhibitor could override resistance, though development of clinical ABCG2 inhibitors is at the investigational stage<sup><xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R8" ref-type="bibr">8</xref></sup>.</p>
            <p id="P4">In contrast, mutation-based resistance mechanisms were observed in Ba/F3 BCR-ABL1<sup>asciminib-R</sup> and KCL-22<sup>asciminib-R</sup> cells. In Ba/F3 BCR-ABL1<sup>asciminib-R</sup> cells, a &gt;1,000-fold increase in asciminib IC<sub>50</sub> over Ba/F3 BCR-ABL1 cells was observed, despite undiminished sensitivity to ATP-site TKIs (<xref rid="F2" ref-type="fig">Figure 2a</xref>; <xref rid="SD6" ref-type="supplementary-material">Table S1</xref>). While immunoblot analysis demonstrated restored BCR-ABL1 signaling in Ba/F3 BCR-ABL1<sup>asciminib-R</sup> cells treated with asciminib (<xref rid="SD3" ref-type="supplementary-material">Figure S4a</xref>), LC-MS/MS analysis showed similar amounts of asciminib in Ba/F3 BCR-ABL1 and Ba/F3 BCR-ABL1<sup>asciminib-R</sup> cells and there was no evidence of efflux pump involvement (<xref rid="SD3" ref-type="supplementary-material">Figure S4b</xref>–<xref rid="SD3" ref-type="supplementary-material">e</xref>). NGS and Sanger sequencing of the <italic>BCR-ABL1</italic> kinase domain identified a novel BCR-ABL1<sup>C464W</sup> mutation (<xref rid="SD7" ref-type="supplementary-material">Table S2</xref>), which was demonstrated through computational modeling to block access of asciminib to the myristoyl-binding pocket, consistent with high-level resistance (<xref rid="F2" ref-type="fig">Figure 2b</xref>). While other BCR-ABL1 mutations within or near the myristoyl-binding pocket (e.g. A337V; P465S; V468F) have been recently reported to confer asciminib resistance<sup><xref rid="R1" ref-type="bibr">1</xref></sup>, this is the first report of BCR-ABL1<sup>C464W</sup> as an asciminib-resistant mutant.</p>
            <p id="P5">KCL-22<sup>asciminib-R</sup> cells exhibited two mutations at similar allelic frequencies<sup><xref rid="R9" ref-type="bibr">9</xref></sup>: BCR-ABL1<sup>M244V</sup> near the ATP site and BCR-ABL1<sup>A337V</sup> in the myristoyl-binding pocket (<xref rid="SD7" ref-type="supplementary-material">Table S2</xref>), and single-cell sorting followed by clonal sequencing revealed a BCR-ABL1<sup>M244V/A337V</sup> compound mutation<sup><xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref></sup>. KCL-22<sup>asciminib-R</sup> cells were completely insensitive to asciminib (IC<sub>50</sub>: 10,000 nM as compared to 2.2 nM for parental KCL-22 cells), but remained sensitive to ATP-site TKIs (<xref rid="F2" ref-type="fig">Figure 2c</xref>; <xref rid="SD4" ref-type="supplementary-material">Figure S5a</xref>; <xref rid="SD6" ref-type="supplementary-material">Table S1</xref>). LC/MS-MS showed comparable intracellular asciminib levels in KCL-22<sup>asciminib-R</sup> and KCL-22 cells, and there was no evidence of either altered effectiveness of asciminib against KCL-22<sup>asciminib-R</sup> cells by inclusion of an efflux pump inhibitor or upregulation of an efflux pump by qPCR or ABCG2 immunoblot (<xref rid="SD4" ref-type="supplementary-material">Figure S5b</xref>–<xref rid="SD4" ref-type="supplementary-material">e</xref>). Sequencing of increasingly asciminib-resistant cells collected in the process of generating the final KCL-22<sup>asciminib-R</sup> cell line revealed a progression from BCR-ABL1<sup>A337V</sup> to BCR-ABL1<sup>M244V/A337V</sup> (<xref rid="F2" ref-type="fig">Figure 2d</xref>). The reported asciminib IC<sub>50</sub> value of 702 nM for KCL-22<sup>A337V</sup> cells<sup><xref rid="R1" ref-type="bibr">1</xref></sup> is consistent with the inability of this mutation alone to confer the high-level resistance observed in KCL-22<sup>asciminib-R</sup> cells. The BCR-ABL1<sup>M244V/A337V</sup> compound mutant confers high-level asciminib resistance but inclusion of clinically achievable concentrations of imatinib lead to outgrowth of BCR-ABL1<sup>S229P/T315I</sup> at the expense of BCR-ABL1<sup>M244V/A337V</sup> (<xref rid="SD2" ref-type="supplementary-material">Figure S6</xref>), highlighting a potential complication of addressing asciminib resistance by switching to or including an ATP-site TKI.</p>
            <p id="P6">Taken together, our findings suggest that mechanisms of acquired resistance to the allosteric BCR-ABL1 inhibitor asciminib involve restoration of BCR-ABL1 signaling, due to either asciminib efflux or select <italic>BCR-ABL1</italic> mutations. It may be possible to override ABCG2-mediated drug efflux by dose escalation of asciminib. The achievable clinical dose is estimated to be at least 1 μM<sup><xref rid="R12" ref-type="bibr">12</xref></sup>. Another possibility to circumvent this resistance mechanism is to design a next-generation allosteric inhibitor that is not a substrate for efflux pump(s). While development of a next-generation allosteric inhibitor<sup><xref rid="R13" ref-type="bibr">13</xref></sup> is possible, the potential for cross-resistant myristoyl-binding pocket mutations may be high, as those observed for asciminib to date completely block inhibitor access to the binding pocket. Alternatively, myristoyl-binding site mutation-based resistance to asciminib could be countered with a TKI that binds at the ATP site, though such a mutation occurring in tandem with an additional kinase domain mutation could result in resistance to both types of inhibitor. The strategy of simultaneously treating with asciminib and an ATP-site TKI (imatinib, nilotinib or dasatinib) to minimize opportunity for resistance is under clinical investigation. Ponatinib, which has activity against the T315I mutant and reported potency as an ABCG2 inhibitor<sup><xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref></sup>, may also warrant consideration in this setting.</p>
            <sec sec-type="supplementary-material" id="SM1">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="SD1">
                <label>SuppFiguresAndTableLegends</label>
                <media xlink:href="NIHMS890534-supplement-SuppFiguresAndTableLegends.docx" orientation="portrait" id="d39e511" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD2">
                <label>890534_FigS6</label>
                <media xlink:href="NIHMS890534-supplement-890534_FigS6.png" orientation="portrait" id="d39e515" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD3">
                <label>890534_FigS4</label>
                <media xlink:href="NIHMS890534-supplement-890534_FigS4.png" orientation="portrait" id="d39e519" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD4">
                <label>890534_FigS5</label>
                <media xlink:href="NIHMS890534-supplement-890534_FigS5.png" orientation="portrait" id="d39e523" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD5">
                <label>890534_SuppMethods</label>
                <media xlink:href="NIHMS890534-supplement-890534_SuppMethods.pdf" orientation="portrait" id="d39e527" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD6">
                <label>890534_TableS1</label>
                <media xlink:href="NIHMS890534-supplement-890534_TableS1.png" orientation="portrait" id="d39e531" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD7">
                <label>890534_TableS2</label>
                <media xlink:href="NIHMS890534-supplement-890534_TableS2.png" orientation="portrait" id="d39e535" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD8">
                <label>890534_FigS1</label>
                <media xlink:href="NIHMS890534-supplement-890534_FigS1.png" orientation="portrait" id="d39e539" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD9">
                <label>890534_FigS2</label>
                <media xlink:href="NIHMS890534-supplement-890534_FigS2.png" orientation="portrait" id="d39e543" position="anchor"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SD10">
                <label>890534_FigS3</label>
                <media xlink:href="NIHMS890534-supplement-890534_FigS3.png" orientation="portrait" id="d39e547" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="S1">
              <title>ACKNOWLEDGEMENTS</title>
              <p id="P7">WQ is supported by NSFC (81400105) and Science and Technology Planning Project of Guangdong (2014A020212185). This work was supported by NIH/NCI R01CA178397 (MD, TO) and Cancer Center Support Grant P30CA042014.</p>
            </ack>
            <fn-group>
              <fn fn-type="COI-statement" id="FN2">
                <p id="P8">CONFLICT OF INTEREST</p>
                <p id="P9">TWK has financial interests to declare: Novartis speaker’s bureau, Novartis advisory board. DR receives honoraria from BMS, Novartis, Incyte and Pfizer for non-promotional scientific lectures or advisory boards and is an investigator of Novartis-sponsored CABL001X2101 phase I trial. The other authors declare no conflict of interest.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><name><surname>Wylie</surname><given-names>AA</given-names></name>, <name><surname>Schoepfer</surname><given-names>J</given-names></name>, <name><surname>Jahnke</surname><given-names>W</given-names></name>, <name><surname>Cowan-Jacob</surname><given-names>SW</given-names></name>, <name><surname>Loo</surname><given-names>A</given-names></name>, <name><surname>Furet</surname><given-names>P</given-names></name>, <etal/><article-title>The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1</article-title>. <source>Nature</source><year>2017</year>; <volume>543</volume>: <fpage>733</fpage>–<lpage>737</lpage>.<pub-id pub-id-type="pmid">28329763</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><name><surname>Gray</surname><given-names>NS</given-names></name>, <name><surname>Fabbro</surname><given-names>D</given-names></name>. <article-title>Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate</article-title>. <source>Methods Enzymol</source><year>2014</year>; <volume>548</volume>: <fpage>173</fpage>–<lpage>188</lpage>.<pub-id pub-id-type="pmid">25399646</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><name><surname>Adrian</surname><given-names>FJ</given-names></name>, <name><surname>Ding</surname><given-names>Q</given-names></name>, <name><surname>Sim</surname><given-names>T</given-names></name>, <name><surname>Velentza</surname><given-names>A</given-names></name>, <name><surname>Sloan</surname><given-names>C</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <etal/><article-title>Allosteric inhibitors of Bcr-abl-dependent cell proliferation</article-title>. <source>Nat Chem Biol</source><year>2006</year>; <volume>2</volume>: <fpage>95</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">16415863</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Adrian</surname><given-names>FJ</given-names></name>, <name><surname>Jahnke</surname><given-names>W</given-names></name>, <name><surname>Cowan-Jacob</surname><given-names>SW</given-names></name>, <name><surname>Li</surname><given-names>AG</given-names></name>, <name><surname>Iacob</surname><given-names>RE</given-names></name>, <etal/><article-title>Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors</article-title>. <source>Nature</source><year>2010</year>; <volume>463</volume>: <fpage>501</fpage>–<lpage>506</lpage>.<pub-id pub-id-type="pmid">20072125</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><name><surname>Szankasi</surname><given-names>P</given-names></name>, <name><surname>Schumacher</surname><given-names>JA</given-names></name>, <name><surname>Kelley</surname><given-names>TW</given-names></name>. <article-title>Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing</article-title>. <source>Ann Hematol</source><year>2016</year>; <volume>95</volume>: <fpage>201</fpage>–<lpage>210</lpage>.<pub-id pub-id-type="pmid">26555285</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><name><surname>O’Hare</surname><given-names>T</given-names></name>, <name><surname>Eide</surname><given-names>CA</given-names></name>, <name><surname>Agarwal</surname><given-names>A</given-names></name>, <name><surname>Adrian</surname><given-names>LT</given-names></name>, <name><surname>Zabriskie</surname><given-names>MS</given-names></name>, <name><surname>Mackenzie</surname><given-names>RJ</given-names></name>, <etal/><article-title>Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis</article-title>. <source>Cancer Res</source><year>2013</year>; <volume>73</volume>: <fpage>3356</fpage>–<lpage>3370</lpage>.<pub-id pub-id-type="pmid">23576564</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><name><surname>Miyata</surname><given-names>H</given-names></name>, <name><surname>Takada</surname><given-names>T</given-names></name>, <name><surname>Toyoda</surname><given-names>Y</given-names></name>, <name><surname>Matsuo</surname><given-names>H</given-names></name>, <name><surname>Ichida</surname><given-names>K</given-names></name>, <name><surname>Suzuki</surname><given-names>H</given-names></name>. <article-title>Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations</article-title>. <source>Front Pharmacol</source><year>2016</year>; <volume>7</volume>: <fpage>518</fpage>.<pub-id pub-id-type="pmid">28082903</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><name><surname>Westover</surname><given-names>D</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>. <article-title>New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies</article-title>. <source>J Exp Clin Cancer Res</source><year>2015</year>; <volume>34</volume>: <fpage>159</fpage>.<pub-id pub-id-type="pmid">26714461</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Gao</surname><given-names>C</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Huang</surname><given-names>Q</given-names></name>, <name><surname>Yee</surname><given-names>JK</given-names></name>, <etal/><article-title>BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia</article-title>. <source>J Biol Chem</source><year>2010</year>; <volume>285</volume>: <fpage>5085</fpage>–<lpage>5096</lpage>.<pub-id pub-id-type="pmid">20007699</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><name><surname>Shah</surname><given-names>NP</given-names></name>, <name><surname>Skaggs</surname><given-names>BJ</given-names></name>, <name><surname>Branford</surname><given-names>S</given-names></name>, <name><surname>Hughes</surname><given-names>TP</given-names></name>, <name><surname>Nicoll</surname><given-names>JM</given-names></name>, <name><surname>Paquette</surname><given-names>RL</given-names></name>, <etal/><article-title>Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency</article-title>. <source>J Clin Invest</source><year>2007</year>; <volume>117</volume>: <fpage>2562</fpage>–<lpage>2569</lpage>.<pub-id pub-id-type="pmid">17710227</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><name><surname>Zabriskie</surname><given-names>MS</given-names></name>, <name><surname>Eide</surname><given-names>CA</given-names></name>, <name><surname>Tantravahi</surname><given-names>SK</given-names></name>, <name><surname>Vellore</surname><given-names>NA</given-names></name>, <name><surname>Estrada</surname><given-names>J</given-names></name>, <name><surname>Nicolini</surname><given-names>FE</given-names></name>, <etal/><article-title>BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia</article-title>. <source>Cancer Cell</source><year>2014</year>; <volume>26</volume>: <fpage>428</fpage>–<lpage>442</lpage>.<pub-id pub-id-type="pmid">25132497</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><name><surname>Ottman</surname><given-names>OG</given-names></name>, <name><surname>Alimena</surname><given-names>G</given-names></name>, <name><surname>DeAngelo</surname><given-names>DJ</given-names></name>, <name><surname>Goh</surname><given-names>Y-T</given-names></name>, <name><surname>Heinrich</surname><given-names>MC</given-names></name>, <name><surname>Hochhaus</surname><given-names>A</given-names></name>, <etal/><article-title>ABL001, a potent, allosteric inhibitor or BCR-ABL, exhibits safety and promising single-agent activity in a phase I study of patients with CML with failure of prior TKI therapy</article-title>. <source>Blood</source><year>2015</year>; <volume>126</volume>.</mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><name><surname>Deng</surname><given-names>X</given-names></name>, <name><surname>Okram</surname><given-names>B</given-names></name>, <name><surname>Ding</surname><given-names>Q</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Choi</surname><given-names>Y</given-names></name>, <name><surname>Adrian</surname><given-names>FJ</given-names></name>, <etal/><article-title>Expanding the diversity of allosteric BCR-ABL inhibitors</article-title>. <source>J Med Chem</source><year>2010</year>; <volume>53</volume>: <fpage>6934</fpage>–<lpage>6946</lpage>.<pub-id pub-id-type="pmid">20828158</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><name><surname>Sen</surname><given-names>R</given-names></name>, <name><surname>Natarajan</surname><given-names>K</given-names></name>, <name><surname>Bhullar</surname><given-names>J</given-names></name>, <name><surname>Shukla</surname><given-names>S</given-names></name>, <name><surname>Fang</surname><given-names>HB</given-names></name>, <name><surname>Cai</surname><given-names>L</given-names></name>, <etal/><article-title>The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2</article-title>. <source>Mol Cancer Ther</source><year>2012</year>; <volume>11</volume>: <fpage>2033</fpage>–<lpage>2044</lpage>.<pub-id pub-id-type="pmid">22778153</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><name><surname>Lu</surname><given-names>L</given-names></name>, <name><surname>Saunders</surname><given-names>VA</given-names></name>, <name><surname>Leclercq</surname><given-names>TM</given-names></name>, <name><surname>Hughes</surname><given-names>TP</given-names></name>, <name><surname>White</surname><given-names>DL</given-names></name>. <article-title>Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells</article-title>. <source>Leukemia</source><year>2015</year>; <volume>29</volume>: <fpage>1792</fpage>–<lpage>1794</lpage>.<pub-id pub-id-type="pmid">25676419</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig id="F1" orientation="portrait" position="float">
              <label>Figure 1.</label>
              <caption>
                <p id="P10">Upregulation of the ABCG2 efflux pump eliminates asciminib from K562<sup>asciminib-R</sup> cells and confers high-level resistance to asciminib. (<bold>a</bold>) K562<sup>asciminib-R</sup> cells retain sensitivity to TKIs that target the ATP site. (<bold>b</bold>) qPCR of candidate efflux pumps and (<italic>inset</italic>) ABCG2 immunoblot confirm ABCG2 upregulation in K562<sup>asciminib-R</sup> cells. (<bold>c</bold>) Inclusion of the ABCG2 inhibitor, Ko143, restores asciminib sensitivity to K562<sup>asciminib-R</sup> cells.</p>
              </caption>
              <graphic xlink:href="nihms-890534-f0001"/>
            </fig>
            <fig id="F2" orientation="portrait" position="float">
              <label>Figure 2.</label>
              <caption>
                <p id="P11"><italic>BCR-ABL1</italic> mutations in the myristoyl-binding pocket and at a remote site confer asciminib resistance. (<bold>a</bold>) Myristoyl-binding site mutation BCR-ABL1<sup>C464W</sup> confers high-level resistance to asciminib but not to ATP-site TKIs. (<bold>b</bold>) Structural analysis of the C464W mutation in the allosteric myristoyl-binding pocket. (<italic>upper left</italic>) Close-up view of the asciminib-bound allosteric pocket. For visualization of the deeper pocket some residues are not shown. The C<sup>α</sup> position of the C464 residue is highlighted in red, while the sidechain is partially buried inside the pocket. (<italic>upper right</italic>) C464W mutation occupies the deep hydrophobic cleft due to its bulky sidechain, making critical interaction with the αI helix, while blocking access of asciminib. The mutated residue is shown as a space-filling model (highlighted in red). (<italic>lower</italic>) Two sideviews of the asciminib-binding pocket show the native and C464W mutant sidechain alignments with respect to asciminib binding. The first image is oriented to match the preceding images in this panel. The second image is rotated to allow visualization of hydrogen-bonding interaction. The sidechain of C464 is buried in the interior of the protein and participates in thiol-mediated hydrogen bonding with the P465 residue. However, on mutation to W464, the tryptophan sidechain is sterically incompatible with P465 and is forced to occupy the myristoyl-binding pocket, interfering with asciminib binding. (<bold>c</bold>) KCL-22<sup>asciminib-R</sup> cells exhibit high-level resistance to asciminib but not to ATP-site TKIs. (<bold>d</bold>) NGS sequencing of KCL-22 cells, increasingly asciminib-resistant cells collected in the process of generating the final resistant line and the KCL-22<sup>asciminib-R</sup> cell line reveals a progression from BCR-ABL1 through BCR-ABL1<sup>A337V</sup> to BCR-ABL1<sup>M244V/A337V</sup>.</p>
              </caption>
              <graphic xlink:href="nihms-890534-f0002"/>
            </fig>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
